Listed

Minerva Neurosciences, Inc.

NERVNasdaqCIK 1598646HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2021$0Revenue, Q4 FY2021, three months to 2021-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-03-01, accession 0001564590-22-007853. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2021, from the 10-K filed Mar 1, 2022.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.14Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001193125-26-339171.Report this figure+67.4% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Diluted EPS−$0.14, Q2 FY2026
Minerva Neurosciences, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share2.97Diluted EPS, Q3 FY2024, three months to 2024-09-30$2.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-265685.Report this figurenot reported (Diluted EPS not reported)(0.50)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-205182.Report this figure(0.43)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001193125-26-339171.Report this figure(0.36)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-265685.Report this figurenot reported (Diluted EPS not reported)(2.86)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-205182.Report this figure(0.14)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-07, accession 0001193125-26-339171.Report this figure
Free cash flow$not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$0, FY2024
Diluted EPS−$34.67, FY2025
Free cash flow−$24.7m, FY2022
Minerva Neurosciences, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m0.0Revenue, FY2021, twelve months to 2021-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-03-01, accession 0001564590-22-007853.Report this figure0.0Revenue, FY2022, twelve months to 2022-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-08, accession 0000950170-23-006577.Report this figure0.0Revenue, FY2023, twelve months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000950170-24-018392.Report this figure0.0Revenue, FY2024, twelve months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000950170-25-026055.Report this figurenot reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)
Diluted EPS$ per share(9.35)Diluted EPS, FY2021, twelve months to 2021-12-31−$9.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-08, accession 0000950170-23-006577.Report this figure(6.01)Diluted EPS, FY2022, twelve months to 2022-12-31−$6.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0000950170-24-018392.Report this figure(4.61)Diluted EPS, FY2023, twelve months to 2023-12-31−$4.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0000950170-25-026055.Report this figure0.19Diluted EPS, FY2024, twelve months to 2024-12-31$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-11, accession 0001193125-26-101117.Report this figure(34.67)Diluted EPS, FY2025, twelve months to 2025-12-31−$34.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-11, accession 0001193125-26-101117.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)(24.7)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0000950170-24-018392.Capital expenditure: $16.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0000950170-24-018392.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

Minerva Neurosciences, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2015-03-13Johnson & Johnson10% owner Purchase607,903$4.81$2.9mForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Minerva Neurosciences, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FEDERATED HERMES, INC.2026-06-30$25.9m4,670,426Reduced−442,798
JANUS HENDERSON GROUP PLC2026-03-31$25.9m4,294,259Not compared
Jupiter Topco LLC2026-06-30$24.3m4,386,027Not compared
Vivo Capital, LLC2026-06-30$24.0m4,322,747Unchanged
Balyasny Asset Management L.P.2026-06-30$23.6m4,257,000Reduced−1,600
Logos Global Management LP2026-06-30$18.3m3,288,777Added+73,777
FARALLON CAPITAL MANAGEMENT, L.L.C.2026-06-30$13.1m2,365,000Unchanged
BlackRock, Inc.2026-06-30$12.4m2,240,578Added+1,615,721
Ally Bridge Group (NY) LLC2026-06-30$12.1m2,175,802Added+520,302
Foresite Capital Management VI LLC2026-06-30$11.0m1,985,584Reduced−1,016

Recent filings

All 620 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Minerva Neurosciences, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-1216:05 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-346817
2026-08-0707:30 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-339171
2026-08-0707:13 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-339147
2026-06-0416:05 ET8-K3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-257379
2026-05-2716:18 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-241930
2026-05-0508:30 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-205182
2026-05-0508:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-205129
2026-04-2307:00 ETDEF 14AProxy statementPeriod 2026-06-030001193125-26-171799
2026-04-0617:07 ET8-K8.01 Other events0001193125-26-143986
2026-04-0216:15 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-140148

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 11, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1598646
Tickers
NERV
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
MA
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:30 ET. Listed shows no prices and gives no investment advice.